The University of Chicago Header Logo

Connection

Ezra Cohen to Protein Kinase Inhibitors

This is a "connection" page, showing publications Ezra Cohen has written about Protein Kinase Inhibitors.
Connection Strength

3.856
  1. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
    View in: PubMed
    Score: 0.386
  2. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. Clin Cancer Res. 2015 Dec 15; 21(24):5420-6.
    View in: PubMed
    Score: 0.384
  3. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials. 2014 Nov 29; 15:469.
    View in: PubMed
    Score: 0.361
  4. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 12; 74(6):1261-70.
    View in: PubMed
    Score: 0.358
  5. New approaches to thyroid cancer. Clin Adv Hematol Oncol. 2012 Apr; 10(4):255-6.
    View in: PubMed
    Score: 0.300
  6. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24.
    View in: PubMed
    Score: 0.270
  7. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009 Oct; 45(10):e155-60.
    View in: PubMed
    Score: 0.248
  8. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8.
    View in: PubMed
    Score: 0.193
  9. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol. 2006 Jan; 57(1):25-43.
    View in: PubMed
    Score: 0.191
  10. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer. JCO Oncol Pract. 2024 Jul; 20(7):899-906.
    View in: PubMed
    Score: 0.171
  11. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16.
    View in: PubMed
    Score: 0.098
  12. Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1279-89.
    View in: PubMed
    Score: 0.090
  13. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46.
    View in: PubMed
    Score: 0.083
  14. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013 Jun; 13(6):729-36.
    View in: PubMed
    Score: 0.080
  15. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45.
    View in: PubMed
    Score: 0.070
  16. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck. 2011 Dec; 33(12):1774-82.
    View in: PubMed
    Score: 0.070
  17. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010 Feb; 19(2):358-65.
    View in: PubMed
    Score: 0.064
  18. Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck. 2009 Aug; 31(8):1086-94.
    View in: PubMed
    Score: 0.062
  19. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.061
  20. Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. Dis Esophagus. 2008; 21(6):514-21.
    View in: PubMed
    Score: 0.056
  21. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets. 2007 Nov; 7(7):666-73.
    View in: PubMed
    Score: 0.055
  22. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006 Jun 15; 66(12):6296-303.
    View in: PubMed
    Score: 0.050
  23. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006 Jun 10; 24(17):2659-65.
    View in: PubMed
    Score: 0.050
  24. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383.
    View in: PubMed
    Score: 0.035
  25. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017 Aug 15; 23(16):4716-4723.
    View in: PubMed
    Score: 0.027
  26. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2014 Jun; 73(6):1227-39.
    View in: PubMed
    Score: 0.022
  27. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer. 2014 Mar; 50(5):876-84.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.